TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01945294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: 800 mg three times daily orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: 800 mg three times daily orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: 800 mg three times daily orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peg-interferon alfa-2b
Description: 1.5 mcg/kg weekly subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peg-interferon alfa-2b
Description: 1.5 mcg/kg weekly subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peg-interferon alfa-2b
Description: 1.5 mcg/kg weekly subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 800-1400 mg twice-daily divided orally based on body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 800-1400 mg twice-daily divided orally based on body weight
Study: NCT02108418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG-2349 as the original formulation
Description: single oral dose under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG-2349 as a new capsule formulation
Description: single oral dose under fed condition
Study: NCT02026505

Intervention type: DRUG
Intervention: Bortezomib
Study: NCT04226651

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Device
Description: The Virtual Reality system (PlayStation 4 VR, Sony Inc.) is a simple and easy to use distraction device. The system consists of a screen mounted on a binocular headset connected to a console or personal computer. The head-mounted display provides a high-resolution visual display and unmutes the sound from the headphones using a soundproof mechanism that provides clear sound.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Protective glasses
Description: Each patient was informed about the dental procedure and was provided with protective glasses. All patients were told that they were wearing these glasses to ensure a pain- and stress-free treatment, and that the dentist would devote additional attention to the treatment.
Study: NCT01039259

Intervention type: DEVICE
Intervention: piercings of four different materials
Description: randomly assigned sterile piercings are inserted for two weeks

Intervention type: DEVICE
Intervention: piercings of four different materials
Description: randomly assigned sterile piercings are inserted for two weeks
Study: NCT02859558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy
Description: Participants received one tablet of elvitegravir 150mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg by mouth daily with food or one tablet of bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg by mouth daily with or without food. Other non-study-provided ARV regimens were allowed for participants who were pregnant, breastfeeding, or unable/unwilling to take EVG/COBI/FTC/TAF or BIC/FTC/TAF, or for participants whose local health care/primary care provider preferred starting a different initial ARV regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy
Description: Participants received one tablet of elvitegravir 150mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg by mouth daily with food or one tablet of bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg by mouth daily with or without food. Other non-study-provided ARV regimens were allowed for participants who were pregnant, breastfeeding, or unable/unwilling to take EVG/COBI/FTC/TAF or BIC/FTC/TAF, or for participants whose local health care/primary care provider preferred starting a different initial ARV regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy
Description: Participants received one tablet of elvitegravir 150mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg by mouth daily with food or one tablet of bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg by mouth daily with or without food. Other non-study-provided ARV regimens were allowed for participants who were pregnant, breastfeeding, or unable/unwilling to take EVG/COBI/FTC/TAF or BIC/FTC/TAF, or for participants whose local health care/primary care provider preferred starting a different initial ARV regimen.
Study: NCT03394183

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Rehabilitation
Description: Cardiac rehabilitation is a 6 month program in which patients enrolled attend weekly classes which consist of individualized exercise and risk factor education lectures. This intervention is consistent with standard care procedures for the Cardiovascular Prevention and Rehabilitation Program at the Toronto Rehabilitation Institute Rumsey Centre.
Study: NCT01945294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 800-1400 mg twice-daily divided orally based on body weight
Study: NCT01839799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2 IV over 30 to 100 minutes, day 1, 8, 15
Study: NCT03394183

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation
Description: Cardiac rehabilitation is a 6 month program in which patients enrolled attend weekly classes which consist of individualized exercise and risk factor education lectures. This intervention is consistent with standard care procedures for the Cardiovascular Prevention and Rehabilitation Program at the Toronto Rehabilitation Institute Rumsey Centre.
Study: NCT00564564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Quetiapine once a day at maximum dosage of 200mg per day asociated to a SSRI (maximum dosage of 40mg per day for fluoxetine; 200mg per day for sertraline and 60mg per day for citalopram)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomipramine
Description: Clomipramine once a day at maximum dosage of 75mg per day plus SSRI (maximum dosage of 40mg per day for fluoxetine; 200mg per day for sertraline and 60mg per day for citalopram)
Study: NCT03429595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATx201
Description: ATx201 GEL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATx201
Description: ATx201 GEL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATx201
Description: ATx201 GEL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATx201
Description: ATx201 GEL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ATx201 GEL Vehicle
Description: Vehicle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ATx201 GEL Vehicle
Description: Vehicle

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ATx201 GEL Vehicle
Description: Vehicle
Study: NCT03377725

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine
Description: 20mg/m\^2,d1-5,ivgtt,28days as a duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 20mg/m\^2,d1-5,ivgtt,28days as a duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide
Description: 0.16mg/kg,d1-5,ivgtt,28days as a duration
Study: NCT01630395

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: protective ventilation
Description: low tidal volume and PEEP

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Recruitment maneuver combined with protective ventilation
Description: Low tidal volume, PEEP and recruitment maneuver
Study: NCT01601717

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RTI-336
Description: Four medication dosage groups (0 mg, 1 mg, 12 mg, 20 mg) administered in the form of a pill once per day for 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo pill administered once per day for 10 days.
Study: NCT01628341

Intervention type: DRUG
Intervention: insulin
Description: Patients will be asked to complete 2 self-assessment questionnaires
Study: NCT02960256

Intervention type: DEVICE
Intervention: ekocardiogram test
Description: ekocardiogram test
Study: NCT04196829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: silver diamine fluoride ⁄ potassium Iodide
Description: The affected tooth surface will be gently cleaned and dried with cotton gauze. The gingival tissue of the tooth will be protected with petroleum jelly. An applicator will be dipped into the SDF and 3-4 mg applied to the lesion with microbrush which will be used to paint solution over carious lesion then we will wait for 1 minute till absorption . Then after SDF application KI will be applied using a separate microbrush which will be saturated by the solution and will be used to paint solution over carious lesion , no rinse will be performed and special instructions will be given following application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver Diamine Fluoride
Description: The affected tooth surface will be gently cleaned and dried with cotton gauze. The gingival tissue of the tooth will be protected with petroleum jelly. An applicator will be dipped into the SDF and 3-4 mg applied to the lesion with microbrush which will be used to paint solution over carious lesion then we will wait for 1 minute till absorption .
Study: NCT00305097

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee
Description: 5 cups per day for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Description: 5 cups per day for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: No coffee
Study: NCT03000647

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor exercises guided by a physiotherapist
Description: Subjects perform two types of contractions of the pelvic floor in two different positions 3 times a day and once a week they check it with a physiotherapist (this day only they do it twice at home)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non guided pelvic floor exercises
Description: Subjects perform two types of contractions of the pelvic floor in two different positions 3 times a day. They do not attend to meetings with a physiotherapist
Study: NCT04526314

Intervention type: OTHER
Intervention: observational
Description: observational

Intervention type: OTHER
Intervention: observational
Description: observational
Study: NCT03614221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lindioil ointment
Description: Each gram contains 200µg of indirubin. Apply 0.5 g of ointment per 10 cm x 10 cm of affected skin areas twice daily for 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lindioil ointment
Description: Each gram contains 200µg of indirubin. Apply 0.5 g of ointment per 10 cm x 10 cm of affected skin areas twice daily for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Protopic ointment 0.1%
Description: Each gram contains (w/w) 0.1% of tacrolimus. Apply 0.1 g of ointment per 10 cm x 10 cm of affected skin areas twice daily for 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Protopic ointment 0.1%
Description: Each gram contains (w/w) 0.1% of tacrolimus. Apply 0.1 g of ointment per 10 cm x 10 cm of affected skin areas twice daily for 6 weeks.
Study: NCT00740597

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: western blotting

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Study: NCT01839799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: 125 mg/m2 IV over 30 minutes, day 1, 8, 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: Irinotecan 180 mg/m2 Day 1 Oxaliplatin 85 mg/m2 Day 1 5-FU 400 mg/m2 bolus with Leucovorin 200 mg/m2 over 2h, Day 1, then 5-FU 2400 mg/m2 over 46h. Four cycles, if tolerated
Study: NCT02358083

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Communication about Vaccination
Description: There are 12 pairs of messages varying in target vaccination, discussion of relative safety of vaccination, and strength of provider recommendation for vaccination.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Communication about Vaccination
Description: There are 12 pairs of messages varying in target vaccination, discussion of relative safety of vaccination, and strength of provider recommendation for vaccination.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Communication about Vaccination
Description: There are 12 pairs of messages varying in target vaccination, discussion of relative safety of vaccination, and strength of provider recommendation for vaccination.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Communication about Vaccination
Description: There are 12 pairs of messages varying in target vaccination, discussion of relative safety of vaccination, and strength of provider recommendation for vaccination.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Communication about Vaccination
Description: There are 12 pairs of messages varying in target vaccination, discussion of relative safety of vaccination, and strength of provider recommendation for vaccination.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Communication about Vaccination
Description: There are 12 pairs of messages varying in target vaccination, discussion of relative safety of vaccination, and strength of provider recommendation for vaccination.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Communication about Vaccination
Description: There are 12 pairs of messages varying in target vaccination, discussion of relative safety of vaccination, and strength of provider recommendation for vaccination.
Study: NCT01839799

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Study: NCT03117881

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DirectCAM
Description: The intervention consists of a 60-minute Complementary Alternative Medicine (CAM) program that includes yoga, Pilates and dual-functioning exercises, which is delivered 2 times per week for the first 8 weeks and 1 time per week for the following 4 weeks at a clinic with a therapist. At the end of week 12, participants will be asked to continue the program in their home for up to 1 year post-intervention using handouts.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TeleCAM
Description: The intervention consists of a 60-minute Complementary Alternative Medicine (CAM) program that includes yoga, Pilates and dual-functioning exercises, which is delivered 2 times per week for the first 8 weeks and 1 time per week for the following 4 weeks at home via videos. At the end of week 12, participants will be asked to continue the program in their home for up to 1 year post-intervention using the videos.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: rDirectCAM
Description: The intervention consists of a 60-minute Complementary Alternative Medicine (CAM) program that includes yoga, Pilates and dual-functioning exercises, which is delivered 2 times per week for the first 8 weeks and 1 time per week for the following 4 weeks by a therapist via videoconferencing technology. At the end of week 12, participants will be asked to continue the program in their home for up to 1 year post-intervention using handouts.
Study: NCT03973333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMC-C103C
Description: Weekly IV infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMC-C103C
Description: Weekly IV infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMC-C103C
Description: Weekly IV infusions
Study: NCT02358083

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Communication about Vaccination
Description: There are 12 pairs of messages varying in target vaccination, discussion of relative safety of vaccination, and strength of provider recommendation for vaccination.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Communication about Vaccination
Description: There are 12 pairs of messages varying in target vaccination, discussion of relative safety of vaccination, and strength of provider recommendation for vaccination.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Communication about Vaccination
Description: There are 12 pairs of messages varying in target vaccination, discussion of relative safety of vaccination, and strength of provider recommendation for vaccination.
Study: NCT00841607

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pancreaticojejunostomy vs pancreaticogastrostomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pancreaticojejunostomy vs pancreaticogastrostomy
Study: NCT03973333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: IV infusions every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMC-C103C
Description: Weekly subcutaneous Injection
Study: NCT02967809

Intervention type: DEVICE
Intervention: echography
Description: cardiac and pulmonary echography
Study: NCT00635570

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ortho Tri-cyclen Lo
Description: Low dose oral contraceptive

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NuvaRing
Description: Contraceptive vaginal ring
Study: NCT02176356

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: onabotulinumtoxinA
Description: onabotulinumtoxinA (BOTOX® Cosmetic) 20U total dose per treatment to glabellar areas and/or 24U total dose per treatment to crow's feet line areas.

Intervention type: DRUG
Group type: OTHER
Intervention: bimatoprost ophthalmic solution 0.03%
Description: bimatoprost ophthalmic solution 0.03% (LATISSE®) 1 drop applied to the upper eyelid at the base of eyelashes once daily in the evening for 17 weeks.

Intervention type: DEVICE
Group type: OTHER
Intervention: JUVÉDERM® ULTRA XC
Description: JUVÉDERM® ULTRA XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.

Intervention type: DEVICE
Group type: OTHER
Intervention: JUVÉDERM® ULTRA PLUS XC
Description: JUVÉDERM® ULTRA PLUS XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.

Intervention type: DEVICE
Group type: OTHER
Intervention: JUVÉDERM® VOLUMA® XC
Description: JUVÉDERM® VOLUMA® XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
Study: NCT00306956

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: offer a pacifier
Description: To offer a pacifier to normal newborn infants at 15 days of age

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: offer a pacifier
Description: To offer a pacifier to normal newborn infants at 15 days of age
Study: NCT03583411

Intervention type: OTHER
Intervention: Epidemiological data collection
Description: To profile each subject enrolled in the study, anamnesis and different personal, clinical, procedural, pharmacological and follow up related variables will be collected. Data collection, maintenance and analysis will be performed using a database that will be developed, managed and updated by study promoter, in accordance with Good Clinical Practice (GCP)
Study: NCT03876002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]PBR06
Description: Subjects will undergo PET imaging using 1 single intravenous (IV) injection of \[18F\]PBR06, a PET radioligand for evaluation of microglial activation in the brain. PBR06 will be injected intravenously as a bolus at a dose of no more than 5.5mCi (millicurie).
Study: NCT02450617

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional individual treatment
Description: Individual psychotherapeutic treatment and case-management delivered by public outpatient clinics or private practicing psychologist/psychiatrist

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional individual treatment
Description: Individual psychotherapeutic treatment and case-management delivered by public outpatient clinics or private practicing psychologist/psychiatrist

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional individual treatment
Description: Individual psychotherapeutic treatment and case-management delivered by public outpatient clinics or private practicing psychologist/psychiatrist

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional individual treatment
Description: Individual psychotherapeutic treatment and case-management delivered by public outpatient clinics or private practicing psychologist/psychiatrist

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stabilizing group treatment for PTSD
Description: 20 sessions group psychotherapy for patients with PTSD, focused on psychoeducation and skills-training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stabilizing group treatment for Dissociative disorders
Description: 20 sessions group psychotherapy for patients with PTSD, focused on psychoeducation and skills-training
Study: NCT00157690

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: 70 mg 1x weekly for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 70 mg 1 x weekly for 12 months
Study: NCT02711813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAB08
Description: biologic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAB08
Description: biologic

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03426553

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Riboflavin+UV RBC
Description: 35 patients who met all inclusion and exclusion criteria received transfusion with RBC suspension from whole blood, treated with riboflavin and ultraviolet pathogen reduction technology

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: irradiated RBC
Description: 35 patients who met all inclusion and exclusion criteria received transfusion with irradiated RBC suspension
Study: NCT01330992

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ocular light or darkness exposure
Description: Ocular light or darkness exposure